130 related articles for article (PubMed ID: 19397476)
1. Inhibition of HGF/MET as therapy for malignancy.
Naran S; Zhang X; Hughes SJ
Expert Opin Ther Targets; 2009 May; 13(5):569-81. PubMed ID: 19397476
[TBL] [Abstract][Full Text] [Related]
2. Targeting the HGF/Met signalling pathway in cancer.
Cecchi F; Rabe DC; Bottaro DP
Eur J Cancer; 2010 May; 46(7):1260-70. PubMed ID: 20303741
[TBL] [Abstract][Full Text] [Related]
3. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
4. MET pathway as a therapeutic target.
Kim ES; Salgia R
J Thorac Oncol; 2009 Apr; 4(4):444-7. PubMed ID: 19333071
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of MET/HGF inhibitors in oncology.
Scagliotti GV; Novello S; von Pawel J
Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
[TBL] [Abstract][Full Text] [Related]
6. HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.
Yap TA; Sandhu SK; Alam SM; de Bono JS
Curr Drug Targets; 2011 Dec; 12(14):2045-58. PubMed ID: 21777195
[TBL] [Abstract][Full Text] [Related]
7. The function, proteolytic processing, and histopathology of Met in cancer.
Hanna JA; Bordeaux J; Rimm DL; Agarwal S
Adv Cancer Res; 2009; 103():1-23. PubMed ID: 19854350
[TBL] [Abstract][Full Text] [Related]
8. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
[TBL] [Abstract][Full Text] [Related]
9. Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors.
Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG
Lancet Oncol; 2009 Jul; 10(7):709-17. PubMed ID: 19573800
[TBL] [Abstract][Full Text] [Related]
10. Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion.
Xie Q; Gao CF; Shinomiya N; Sausville E; Hay R; Gustafson M; Shen Y; Wenkert D; Vande Woude GF
Oncogene; 2005 May; 24(23):3697-707. PubMed ID: 15782129
[TBL] [Abstract][Full Text] [Related]
11. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.
Koeppen H; Rost S; Yauch RL
J Pathol; 2014 Jan; 232(2):210-8. PubMed ID: 24105670
[TBL] [Abstract][Full Text] [Related]
12. Targeting the HGF/c-Met axis: state of play.
Yap TA; de Bono JS
Mol Cancer Ther; 2010 May; 9(5):1077-9. PubMed ID: 20442310
[No Abstract] [Full Text] [Related]
13. Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways.
Bowers DC; Fan S; Walter KA; Abounader R; Williams JA; Rosen EM; Laterra J
Cancer Res; 2000 Aug; 60(15):4277-83. PubMed ID: 10945642
[TBL] [Abstract][Full Text] [Related]
14. Pseudo-active sites of protease domains: HGF/Met and Sonic hedgehog signaling in cancer.
Maun HR; Kirchhofer D; Lazarus RA
Biol Chem; 2010 Aug; 391(8):881-92. PubMed ID: 20536384
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.
Owusu BY; Bansal N; Venukadasula PK; Ross LJ; Messick TE; Goel S; Galemmo RA; Klampfer L
Oncotarget; 2016 May; 7(20):29492-506. PubMed ID: 27121052
[TBL] [Abstract][Full Text] [Related]
16. The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas.
Mahtouk K; Tjin EP; Spaargaren M; Pals ST
Biochim Biophys Acta; 2010 Dec; 1806(2):208-19. PubMed ID: 20655987
[TBL] [Abstract][Full Text] [Related]
17. Targeting c-MET/HGF signaling pathway in upper gastrointestinal cancers: rationale and progress.
Gholamin S; Fiuji H; Maftouh M; Mirhafez R; Shandiz FH; Avan A
Curr Drug Targets; 2014; 15(14):1302-11. PubMed ID: 25382190
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions.
Matsumoto K; Nakamura T
Int J Cancer; 2006 Aug; 119(3):477-83. PubMed ID: 16453287
[TBL] [Abstract][Full Text] [Related]
19. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists.
Michieli P; Basilico C; Pennacchietti S; Maffè A; Tamagnone L; Giordano S; Bardelli A; Comoglio PM
Oncogene; 1999 Sep; 18(37):5221-31. PubMed ID: 10498872
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
